• Product Development
• Statistics and Data Management

Opyl (ASX: OPL) is a global pioneer in AI-assisted clinical trial solutions, specialising in transforming clinical trial design and optimisation through its flagship product, TrialKey. Leveraging over 20 years of real-world data and advanced analytics, TrialKey is a leader in data-driven biostatistical validation, capable of analysing extensive datasets to generate optimised trial designs. 

TrialKey is an AI-driven clinical trial simulator that provides data validation and optimises trial designs to improve success rates. It identifies the best inclusion and exclusion criteria, streamlines patient recruitment, and recommends optimal sites on a global scale. Through its custom reports, TrialKey offers comprehensive insights into competitor trials, enrolment numbers, study durations, and primary endpoints, automating study protocols and enhancing decision-making for researchers, sponsors, and clinicians. With its market-leading accuracy and predictive power, TrialKey ensures trials are efficiently designed, reducing costs and improving outcomes across a wide range of drugs, devices, and novel conditions.

Opyl’s dedication to using advanced AI technologies has positioned it as a trusted partner for researchers and biopharma companies worldwide, driving the future of healthcare innovation and accelerating medical advancements.